JP2008528486A5 - - Google Patents

Info

Publication number

JP2008528486A5

JP2008528486A5 JP2007552110A JP2007552110A JP2008528486A5 JP 2008528486 A5 JP2008528486 A5 JP 2008528486A5 JP 2007552110 A JP2007552110 A JP 2007552110A JP 2007552110 A JP2007552110 A JP 2007552110A JP 2008528486 A5 JP2008528486 A5 JP 2008528486A5

Authority

JP

Japan

Prior art keywords

cancer

antibody

approximately

medicament

medicament according

Prior art date

2005-06-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 39
• 206010028980 Neoplasm Diseases 0.000 claims 14
• 201000011510 cancer Diseases 0.000 claims 13
• 229960002087 pertuzumab Drugs 0.000 claims 9
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 7
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 7
• 206010055113 Breast cancer metastatic Diseases 0.000 claims 6
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
• 239000002246 antineoplastic agent Substances 0.000 claims 5
• 229940127089 cytotoxic agent Drugs 0.000 claims 5
• 238000004519 manufacturing process Methods 0.000 claims 5
• 229940124597 therapeutic agent Drugs 0.000 claims 4
• 206010009944 Colon cancer Diseases 0.000 claims 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
• 201000001342 Fallopian tube cancer Diseases 0.000 claims 3
• 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 3
• 206010033128 Ovarian cancer Diseases 0.000 claims 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
• 206010060862 Prostate cancer Diseases 0.000 claims 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
• 201000002628 peritoneum cancer Diseases 0.000 claims 3
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
• 230000004913 activation Effects 0.000 claims 2
• 230000003321 amplification Effects 0.000 claims 2
• 230000000340 anti-metabolite Effects 0.000 claims 2
• 239000000427 antigen Substances 0.000 claims 2
• 102000036639 antigens Human genes 0.000 claims 2
• 108091007433 antigens Proteins 0.000 claims 2
• 229940100197 antimetabolite Drugs 0.000 claims 2
• 239000002256 antimetabolite Substances 0.000 claims 2
• 230000014509 gene expression Effects 0.000 claims 2
• 238000003199 nucleic acid amplification method Methods 0.000 claims 2
• NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 claims 1
• 208000002874 Acne Vulgaris Diseases 0.000 claims 1
• 229940124638 COX inhibitor Drugs 0.000 claims 1
• -1 COX inhibitors Substances 0.000 claims 1
• 108090000695 Cytokines Proteins 0.000 claims 1
• 102000004127 Cytokines Human genes 0.000 claims 1
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
• 208000010201 Exanthema Diseases 0.000 claims 1
• 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 108010002386 Interleukin-3 Proteins 0.000 claims 1
• 102100039064 Interleukin-3 Human genes 0.000 claims 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
• 206010028813 Nausea Diseases 0.000 claims 1
• 229940123282 Oncogene inhibitor Drugs 0.000 claims 1
• 101150062264 Raf gene Proteins 0.000 claims 1
• 108700011582 TER 286 Proteins 0.000 claims 1
• 229940123237 Taxane Drugs 0.000 claims 1
• 206010000496 acne Diseases 0.000 claims 1
• 150000001413 amino acids Chemical group 0.000 claims 1
• 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
• 230000003388 anti-hormonal effect Effects 0.000 claims 1
• 229960000397 bevacizumab Drugs 0.000 claims 1
• 229950000772 canfosfamide Drugs 0.000 claims 1
• 229940045200 cardioprotective agent Drugs 0.000 claims 1
• 239000012659 cardioprotective agent Substances 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 150000001875 compounds Chemical class 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims 1
• 201000005884 exanthem Diseases 0.000 claims 1
• 230000001747 exhibiting effect Effects 0.000 claims 1
• 229960005277 gemcitabine Drugs 0.000 claims 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
• 238000005734 heterodimerization reaction Methods 0.000 claims 1
• 230000002631 hypothermal effect Effects 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 229940090044 injection Drugs 0.000 claims 1
• 229940043355 kinase inhibitor Drugs 0.000 claims 1
• 239000002502 liposome Substances 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 230000008693 nausea Effects 0.000 claims 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 108700042226 ras Genes Proteins 0.000 claims 1
• 206010037844 rash Diseases 0.000 claims 1
• 102000005962 receptors Human genes 0.000 claims 1
• 108020003175 receptors Proteins 0.000 claims 1
• 231100000046 skin rash Toxicity 0.000 claims 1
• 238000002626 targeted therapy Methods 0.000 claims 1
• 230000008685 targeting Effects 0.000 claims 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
• 229960000303 topotecan Drugs 0.000 claims 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
• 229960000575 trastuzumab Drugs 0.000 claims 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
• 229960005486 vaccine Drugs 0.000 claims 1